DaVita Inc. (DVA) Covered Calls
DaVita Inc. is a leading provider of kidney care services in the United States and internationally, specializing in dialysis for patients with chronic kidney failure and end-stage renal disease. The company operates a vast network of outpatient dialysis centers and provides related lab services, pharmacy services, and vascular access services. It also engages in integrated kidney care, clinical research, and physician services to improve patient outcomes across the kidney care continuum.
You can sell covered calls on DaVita Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for DVA (prices last updated Thu 4:16 PM ET):
| DaVita Inc. (DVA) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 145.58 | -4.76 | 145.75 | 146.40 | 1.1M | 15 | 10 |
| Covered Calls For DaVita Inc. (DVA) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Apr 17 | 145 | 3.70 | 142.70 | 1.6% | 36.5% | |
| May 15 | 145 | 8.50 | 137.90 | 5.1% | 42.3% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
DaVita Inc. is a cornerstone of the healthcare infrastructure, providing life-sustaining kidney care to hundreds of thousands of patients. The company operates primarily through its massive network of dialysis centers, where it treats end-stage renal disease (ESRD) and chronic kidney disease (CKD). By integrating clinical expertise with a sophisticated operating platform, the firm has become one of the largest providers of specialized renal care in the world.
Core Business and Products
The company primary revenue driver is its U.S. Dialysis segment, which offers outpatient, hospital inpatient, and home-based hemodialysis services. In recent years, the firm has made significant investments in home dialysis technology, allowing patients more flexibility and improving their quality of life. This shift toward home-based care is a key strategic initiative aimed at reducing the overall cost of care while maintaining high clinical standards.
Beyond traditional dialysis, the firm operates a high-growth "Integrated Kidney Care" division. This value-based care model uses AI-driven predictive analytics to anticipate patient hospitalizations and manage comorbidities like diabetes and hypertension. By coordinating care across various settings—from the clinic to the hospital—the company aims to keep patients healthier and out of high-cost acute care environments, aligning its financial incentives with improved patient outcomes.
Competitive Landscape
The kidney care industry is highly consolidated, with a few large players managing the majority of outpatient clinics. The company competes for patient volume, nephrologist partnerships, and government contracts. Key competitors that are publicly traded on major exchanges and feature active, liquid options include:
- Fresenius Medical Care: A primary global competitor that provides both dialysis services and the manufacturing of dialysis equipment.
- Baxter International Inc: A provider of essential medical products, including a major portfolio of renal and hospital products.
- UnitedHealth Group Inc: A massive healthcare conglomerate that competes through its Optum division in integrated care and insurance networks.
- HCA Healthcare Inc: A leading hospital operator that provides inpatient dialysis services and competes in the broader medical facility market.
- Encompass Health Corp: A provider of post-acute healthcare services, including inpatient rehabilitation and home health care.
Strategic Outlook and Innovation
The company strategic focus is centered on navigating the evolving landscape of pharmaceutical innovations, such as GLP-1 weight-loss drugs. Rather than viewing these as a threat, the firm has leveraged clinical data showing that these treatments can improve patient longevity, thereby extending the duration of their care within the company system. This adaptive approach ensures the firm remains resilient even as medical protocols for chronic disease management evolve.
Innovation at the firm also extends to its "DaVita Venture Group," which invests in and develops new products and solutions for kidney disease. This includes digital health tools for remote monitoring and next-generation surgical techniques for vascular access. The long-term goal is to transition from a traditional service provider into a comprehensive, data-driven kidney health management company that leads the industry in both clinical quality and operational efficiency.
| Top 10 Open Interest For Apr 17 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | SLV covered calls | 6. | SPY covered calls | 1. | REPL covered calls | |
| 2. | EEM covered calls | 7. | TLT covered calls | 2. | CMPX covered calls | |
| 3. | NVDA covered calls | 8. | HYG covered calls | 3. | AVTX covered calls | |
| 4. | KWEB covered calls | 9. | EWZ covered calls | 4. | APLD covered calls | |
| 5. | QQQ covered calls | 10. | SOFI covered calls | 5. | OCUL covered calls | |
Want more examples? DV Covered Calls | DVN Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
